J Kellogg Parsons1, Karen Messer2, Kerrin Palazzi3, Sean P Stroup4, David Chang5. 1. Department of Urology, University of California, San Diego Health System2Urologic Cancer Unit, University of California, San Diego Moores Cancer Center, La Jolla3Section of Surgery, VA San Diego Healthcare System, San Diego, California. 2. Division of Biostatistics, University of California, San Diego Moores Cancer Center, La Jolla5Department of Family and Preventive Medicine, University of California, San Diego School of Medicine, La Jolla. 3. Department of Urology, University of California, San Diego Health System2Urologic Cancer Unit, University of California, San Diego Moores Cancer Center, La Jolla. 4. Naval Medical Center San Diego, Urologic Oncology, San Diego, California. 5. Department of Surgery, University of California, San Diego Health System.
Abstract
IMPORTANCE: Surgical innovations disseminate in the absence of coordinated systems to ensure their safe integration into clinical practice, potentially exposing patients to increased risk for medical error. OBJECTIVE: To investigate associations of patient safety with the diffusion of minimally invasive radical prostatectomy (MIRP) resulting from the development of the da Vinci robot. DESIGN, SETTING, AND PARTICIPANTS: A cohort study of 401 325 patients in the Nationwide Inpatient Sample who underwent radical prostatectomy during MIRP diffusion between January 1, 2003, and December 31, 2009. MAIN OUTCOMES AND MEASURES: We used Agency for Healthcare Research and Quality Patient Safety Indicators (PSIs), which measure processes of care and surgical provider performance. We estimated the prevalence of MIRP among all prostatectomies and compared PSI incidence between MIRP and open radical prostatectomy in each year during the study. We also collected estimates of MIRP incidence attributed to the manufacturer of the da Vinci robot. RESULTS: Patients who underwent MIRP were more likely to be white (P = .004), have fewer comorbidities (P = .02), and have undergone surgery in higher-income areas (P = .005). The incidence of MIRP was substantially lower than da Vinci manufacturer estimates. Rapid diffusion onset occurred in 2006, when MIRP accounted for 10.4% (95% CI, 10.2-10.7) of all radical prostatectomies in the United States. In 2005, MIRP was associated with an increased adjusted risk for any PSI (adjusted odds ratio, 2.0; 95% CI, 1.1-3.7; P = .02) vs open radical prostatectomy. Stratification by hospital status demonstrated similar patterns: rapid diffusion onset among teaching hospitals occurred in 2006 (11.7%; 95% CI, 11.3-12.0), with an increased risk for PSI for MIRP in 2005 (adjusted odds ratio, 2.7; 95% CI, 1.4-5.3; P = .004), and onset among nonteaching hospitals occurred in 2008 (27.1%; 95% CI, 26.6-27.7), with an increased but nonsignificant risk for PSI in 2007 (adjusted odds ratio, 2.0; 95% CI, 0.8-5.2; P = .14). CONCLUSIONS AND RELEVANCE: During its initial national diffusion, MIRP was associated with diminished perioperative patient safety. To promote safety and protect patients, the processes by which surgical innovations disseminate into clinical practice require refinement.
IMPORTANCE: Surgical innovations disseminate in the absence of coordinated systems to ensure their safe integration into clinical practice, potentially exposing patients to increased risk for medical error. OBJECTIVE: To investigate associations of patient safety with the diffusion of minimally invasive radical prostatectomy (MIRP) resulting from the development of the da Vinci robot. DESIGN, SETTING, AND PARTICIPANTS: A cohort study of 401 325 patients in the Nationwide Inpatient Sample who underwent radical prostatectomy during MIRP diffusion between January 1, 2003, and December 31, 2009. MAIN OUTCOMES AND MEASURES: We used Agency for Healthcare Research and Quality Patient Safety Indicators (PSIs), which measure processes of care and surgical provider performance. We estimated the prevalence of MIRP among all prostatectomies and compared PSI incidence between MIRP and open radical prostatectomy in each year during the study. We also collected estimates of MIRP incidence attributed to the manufacturer of the da Vinci robot. RESULTS:Patients who underwent MIRP were more likely to be white (P = .004), have fewer comorbidities (P = .02), and have undergone surgery in higher-income areas (P = .005). The incidence of MIRP was substantially lower than da Vinci manufacturer estimates. Rapid diffusion onset occurred in 2006, when MIRP accounted for 10.4% (95% CI, 10.2-10.7) of all radical prostatectomies in the United States. In 2005, MIRP was associated with an increased adjusted risk for any PSI (adjusted odds ratio, 2.0; 95% CI, 1.1-3.7; P = .02) vs open radical prostatectomy. Stratification by hospital status demonstrated similar patterns: rapid diffusion onset among teaching hospitals occurred in 2006 (11.7%; 95% CI, 11.3-12.0), with an increased risk for PSI for MIRP in 2005 (adjusted odds ratio, 2.7; 95% CI, 1.4-5.3; P = .004), and onset among nonteaching hospitals occurred in 2008 (27.1%; 95% CI, 26.6-27.7), with an increased but nonsignificant risk for PSI in 2007 (adjusted odds ratio, 2.0; 95% CI, 0.8-5.2; P = .14). CONCLUSIONS AND RELEVANCE: During its initial national diffusion, MIRP was associated with diminished perioperative patient safety. To promote safety and protect patients, the processes by which surgical innovations disseminate into clinical practice require refinement.
Authors: Patrick S Romano; Jeffrey J Geppert; Sheryl Davies; Marlene R Miller; Anne Elixhauser; Kathryn M McDonald Journal: Health Aff (Millwood) Date: 2003 Mar-Apr Impact factor: 6.301
Authors: William T Lowrance; Elena B Elkin; Lindsay M Jacks; David S Yee; Thomas L Jang; Vincent P Laudone; Bertrand D Guillonneau; Peter T Scardino; James A Eastham Journal: J Urol Date: 2010-02-25 Impact factor: 7.450
Authors: William T Lowrance; James A Eastham; Caroline Savage; A C Maschino; Vincent P Laudone; Christopher B Dechet; Robert A Stephenson; Peter T Scardino; Jaspreet S Sandhu Journal: J Urol Date: 2012-04-11 Impact factor: 7.450
Authors: M A Goldstraw; B J Challacombe; K Patil; P Amoroso; P Dasgupta; R S Kirby Journal: Prostate Cancer Prostatic Dis Date: 2011-08-16 Impact factor: 5.554
Authors: Jim C Hu; Xiangmei Gu; Stuart R Lipsitz; Michael J Barry; Anthony V D'Amico; Aaron C Weinberg; Nancy L Keating Journal: JAMA Date: 2009-10-14 Impact factor: 56.272
Authors: Rohit Tejwani; Brian J Young; Hsin-Hsiao S Wang; Steven Wolf; J Todd Purves; John S Wiener; Jonathan C Routh Journal: J Pediatr Urol Date: 2017-02-22 Impact factor: 1.830
Authors: Jens Uwe Stolzenburg; Iason Kyriazis; Claus Fahlenbrach; Christian Gilfrich; Christian Günster; Elke Jeschke; Gralf Popken; Lothar Weißbach; Christoph von Zastrow; Hanna Leicht Journal: World J Urol Date: 2016-03-24 Impact factor: 4.226
Authors: Aaron M Potretzke; Brent A Knight; John A Brockman; Joel Vetter; Robert S Figenshau; Sam B Bhayani; Brian M Benway Journal: J Robot Surg Date: 2016-04-02
Authors: I Henríquez; A Rodríguez-Antolín; J Cassinello; C Gonzalez San Segundo; M Unda; E Gallardo; J López-Torrecilla; A Juarez; J Arranz Journal: Clin Transl Oncol Date: 2017-08-07 Impact factor: 3.405